The document summarizes 295 vaccines currently in development. It notes that vaccines have successfully prevented diseases like smallpox and measles. Today, biopharmaceutical companies are developing vaccines against malaria, meningococcal disease, and cancers like pancreatic and prostate. Developing new vaccines is challenging and requires thorough testing. Areas of focus include preventing infectious diseases and treating cancers. New scientific areas like genomics may help develop more vaccines to protect against life-threatening illnesses.
Measles, Vaccines, Antibodies and Big Pharma Money
Did you know that the AMA strongly discourages ANY comments by Medical Professionals that cast any doubt on the efficacy of vaccines? Did you also know there are several studies that show vaccines as being ineffective and that the basis of vaccines (formation of antibodies to speed up the immune response) has been shown to be invalid? Learn the truth here. Oh, by the way, no vaccine manufacturer can be held liable for any negative side-effects of their products.
++++++++++++++++++++++++++++++++++++++++++
At http://bergmanchiropractic.com and http://Owners-Guide.com we strive to educate people on natural solutions to health.
-------------------------------------------------------------------------------------
http://www.theArthritisReversalSystem.com is my online video course with 21 videos, 3 manuals and an online forum!
++++++++++++++++++++++++++++++++++++++++++
https://www.owners-guide.com/online-consultation/ for online consults.
_________________________________________________
SUBSCRIBE at http://www.youtube.com/user/johnbchiro
CALL TOLL FREE 1-855-712-0012 to get bonus materials not on YouTube or text your first name and email plus 89869 to 1-817-591-2905.
Professor Ray Borrow, Head of the Vaccine Evaluation Unit of the Health Protection Agency. Given that prevention in better than cure, Professor Borrow provided an insightful round-up of where we are with vaccination against meningitis and septicaemia. Professor Borrow looked not only at the current vaccine programme in the UK, but also future challenges and vaccination in the developing world, particularly in the sub-Saharan meningitis belt in Africa where disease can affect tens of thousands of people during epidemics years.
Measles, Vaccines, Antibodies and Big Pharma Money
Did you know that the AMA strongly discourages ANY comments by Medical Professionals that cast any doubt on the efficacy of vaccines? Did you also know there are several studies that show vaccines as being ineffective and that the basis of vaccines (formation of antibodies to speed up the immune response) has been shown to be invalid? Learn the truth here. Oh, by the way, no vaccine manufacturer can be held liable for any negative side-effects of their products.
++++++++++++++++++++++++++++++++++++++++++
At http://bergmanchiropractic.com and http://Owners-Guide.com we strive to educate people on natural solutions to health.
-------------------------------------------------------------------------------------
http://www.theArthritisReversalSystem.com is my online video course with 21 videos, 3 manuals and an online forum!
++++++++++++++++++++++++++++++++++++++++++
https://www.owners-guide.com/online-consultation/ for online consults.
_________________________________________________
SUBSCRIBE at http://www.youtube.com/user/johnbchiro
CALL TOLL FREE 1-855-712-0012 to get bonus materials not on YouTube or text your first name and email plus 89869 to 1-817-591-2905.
Professor Ray Borrow, Head of the Vaccine Evaluation Unit of the Health Protection Agency. Given that prevention in better than cure, Professor Borrow provided an insightful round-up of where we are with vaccination against meningitis and septicaemia. Professor Borrow looked not only at the current vaccine programme in the UK, but also future challenges and vaccination in the developing world, particularly in the sub-Saharan meningitis belt in Africa where disease can affect tens of thousands of people during epidemics years.
Protection of nature and combating the exploration of wild species to avoid n...Fernando Alcoforado
This article aims to show how to prevent new pandemics based on the opinion of experts and the stage of research aimed at the development of vaccines to immunize the population against the new Coronavirus based on information on the progress of research on vaccines essential to combat Covid 19. As will be presented in the following paragraphs, humanity will have to make profound changes in its relationship with nature to prevent new pandemics from occurring that threaten its very existence and invest heavily in R&D aimed at developing vaccines to face up to current and new viruses.
Vaccination - Need to Address the Serious Concernsjagchat01
Vaccinations have become controversial. Attempts are being made to silence critics without transparently addressing the core issues, thus putting subjects at great risk.
Zika Virus: Medical Countermeasure Development Challenges by Robert W. MaloneJan-Cedric Hansen
Reports of high rates of primary microcephaly and Guillain–Barré syndrome associated with Zika virus infection in French Polynesia and Brazil have raised concerns that the virus circulating in these regions is a rapidly developing neuropathic, teratogenic, emerging infec- tious public health threat. There are no licensed medical countermeasures (vaccines, thera- pies or preventive drugs) available for Zika virus infection and disease. The Pan American Health Organization (PAHO) predicts that Zika virus will continue to spread and eventually reach all countries and territories in the Americas with endemic Aedes mosquitoes. This paper reviews the status of the Zika virus outbreak, including medical countermeasure options, with a focus on how the epidemiology, insect vectors, neuropathology, virology and immunology inform options and strategies available for medical countermeasure develop- ment and deployment.
The study of congenital cytomegalovirus, Rubella and Herpes Simplex Virus-2 i...Apollo Hospitals
The study was conducted to analyze the role of Cytomegalovirus (CMV), Rubella and Herpes Simplex Virus (HSV-2) as an etiological agent in congenital infections in infants. The study was carried out at National Reference Centre i.e. NCDC, Delhi where samples are referred from various government hospitals of Delhi from the period of January 2013–December 2013. The samples were tested for CMV, Rubella and HSV specific IgM antibodies by μ capture ELISA (Enzyme linked Immunoassay).
Hepatitis A is an under rated infectious disease in children , with high morbidity and a major cause of fulminant hepatitis in children.There has been a longstanding debate between the LIVE VACCINE FOR HEPATITIS A AND THE KILLED INACTIVATED VACCINE FOR HEPATITIS A. Recent CDC guidelines and INDIAN ACADEMY OF PEDIATRICS GUIDELINES and recent references were studied before making these slides. Hope you find these useful.
ROTAVIRUS VACCINES IN INDIA .WHICH ONE WILL YOU CHOOSE AND WHY?DR SHAILESH MEHTA
Many brands of Rotavirus vaccine are available in India. However we need to have full evidence based decision making before we choose one rotavirus vaccine over another. This slideshow focuses on the need to have Indian studies which are not there with some of the international brands. Regionwise variability of rotavirus vaccines have prompted ICMR and various other scientific bodies in India to have our own data on efficacy of rotaviral vaccines in Indian scenario. Diarrhoea is a major cause of under 5 mortality in children. After the use of rotavirus vaccines there is a huge reduction of financial burden on our healthcare sytems.
Childhood diarrhoea incidence and severity have decreased ever since rotavirus vaccine was made a part of national immunization schedule.
Bacteria Isolated From the Cerebrio-Spinal Fluid (Csf) of Suspected Cases of ...iosrjce
IOSR Journal of Nursing and health Science is ambitious to disseminate information and experience in education, practice and investigation between medicine, nursing and all the sciences involved in health care. Nursing & Health Sciences focuses on the international exchange of knowledge in nursing and health sciences. The journal publishes peer-reviewed papers on original research, education and clinical practice.
By encouraging scholars from around the world to share their knowledge and expertise, the journal aims to provide the reader with a deeper understanding of the lived experience of nursing and health sciences and the opportunity to enrich their own area of practice. The journal publishes original papers, reviews, special and general articles, case management etc.
Protection of nature and combating the exploration of wild species to avoid n...Fernando Alcoforado
This article aims to show how to prevent new pandemics based on the opinion of experts and the stage of research aimed at the development of vaccines to immunize the population against the new Coronavirus based on information on the progress of research on vaccines essential to combat Covid 19. As will be presented in the following paragraphs, humanity will have to make profound changes in its relationship with nature to prevent new pandemics from occurring that threaten its very existence and invest heavily in R&D aimed at developing vaccines to face up to current and new viruses.
Vaccination - Need to Address the Serious Concernsjagchat01
Vaccinations have become controversial. Attempts are being made to silence critics without transparently addressing the core issues, thus putting subjects at great risk.
Zika Virus: Medical Countermeasure Development Challenges by Robert W. MaloneJan-Cedric Hansen
Reports of high rates of primary microcephaly and Guillain–Barré syndrome associated with Zika virus infection in French Polynesia and Brazil have raised concerns that the virus circulating in these regions is a rapidly developing neuropathic, teratogenic, emerging infec- tious public health threat. There are no licensed medical countermeasures (vaccines, thera- pies or preventive drugs) available for Zika virus infection and disease. The Pan American Health Organization (PAHO) predicts that Zika virus will continue to spread and eventually reach all countries and territories in the Americas with endemic Aedes mosquitoes. This paper reviews the status of the Zika virus outbreak, including medical countermeasure options, with a focus on how the epidemiology, insect vectors, neuropathology, virology and immunology inform options and strategies available for medical countermeasure develop- ment and deployment.
The study of congenital cytomegalovirus, Rubella and Herpes Simplex Virus-2 i...Apollo Hospitals
The study was conducted to analyze the role of Cytomegalovirus (CMV), Rubella and Herpes Simplex Virus (HSV-2) as an etiological agent in congenital infections in infants. The study was carried out at National Reference Centre i.e. NCDC, Delhi where samples are referred from various government hospitals of Delhi from the period of January 2013–December 2013. The samples were tested for CMV, Rubella and HSV specific IgM antibodies by μ capture ELISA (Enzyme linked Immunoassay).
Hepatitis A is an under rated infectious disease in children , with high morbidity and a major cause of fulminant hepatitis in children.There has been a longstanding debate between the LIVE VACCINE FOR HEPATITIS A AND THE KILLED INACTIVATED VACCINE FOR HEPATITIS A. Recent CDC guidelines and INDIAN ACADEMY OF PEDIATRICS GUIDELINES and recent references were studied before making these slides. Hope you find these useful.
ROTAVIRUS VACCINES IN INDIA .WHICH ONE WILL YOU CHOOSE AND WHY?DR SHAILESH MEHTA
Many brands of Rotavirus vaccine are available in India. However we need to have full evidence based decision making before we choose one rotavirus vaccine over another. This slideshow focuses on the need to have Indian studies which are not there with some of the international brands. Regionwise variability of rotavirus vaccines have prompted ICMR and various other scientific bodies in India to have our own data on efficacy of rotaviral vaccines in Indian scenario. Diarrhoea is a major cause of under 5 mortality in children. After the use of rotavirus vaccines there is a huge reduction of financial burden on our healthcare sytems.
Childhood diarrhoea incidence and severity have decreased ever since rotavirus vaccine was made a part of national immunization schedule.
Bacteria Isolated From the Cerebrio-Spinal Fluid (Csf) of Suspected Cases of ...iosrjce
IOSR Journal of Nursing and health Science is ambitious to disseminate information and experience in education, practice and investigation between medicine, nursing and all the sciences involved in health care. Nursing & Health Sciences focuses on the international exchange of knowledge in nursing and health sciences. The journal publishes peer-reviewed papers on original research, education and clinical practice.
By encouraging scholars from around the world to share their knowledge and expertise, the journal aims to provide the reader with a deeper understanding of the lived experience of nursing and health sciences and the opportunity to enrich their own area of practice. The journal publishes original papers, reviews, special and general articles, case management etc.
The causal relation between human papillomavirus and cervical cancerAlberto Cuadrado
J Clin Pathol 2002;55:244–265
The causal role of human papillomavirus infections in
cervical cancer has been documented beyond
reasonable doubt. The association is present in virtually
all cervical cancer cases worldwide. It is the right time
for medical societies and public health regulators to
consider this evidence and to define its preventive and
clinical implications. A comprehensive review of key
studies and results is presented.
"Genomic vaccines promise to offer many advantages, including fast manufacture when a virus, such as Zika or Ebola, suddenly becomes more virulent or widespread”
"Genetic immunization is going to be a revolution in vaccines and now we've taken it to another level - genomic vaccination. We should be able to apply this technology to any pathogen,"
alhajji1alhajji 2Jafar AlhajjiVaccines Safety and Effectiven.docxsimonlbentley59018
alhajji1
alhajji 2
Jafar Alhajji
Vaccines Safety and Effectiveness
Do you think vaccination is an important or just harmful substance forced by pharmaceutical companies cooperating with the governments to inject into people? Vaccine can be defined as “biological preparations that, when introduced into the body, cause an individual to acquire immunity to a specific disease” (Davidson. 7). So, for decades, vaccines have been considered one of the best revaluation in medical practice. A long time ago, people all around the world tried to fight with different kinds of fatal diseases by different ways, and one of the most Significant ways is to make a vaccine, to prevent such life- threatening diseases. The first vaccine was against the Smallpox disease. Smallpox is a highly contagious disease and caused a lot of fatalities all around the world, and it is transmitted between people by inhalation of droplets of virus or direct contact with smallpox lesion secretions (Davidson 25). It is a deadly disease, it caused blindness and permanent scars in the patients that survived. Finally, after several attempts to make a vaccine for Smallpox, Edward succeeded to produce an effective and safe vaccine in 1796 by using the cowpox vaccine to protect from smallpox. Cowpox is a disease cause by cows and transferred to human, and Jenner’s theory was based that whoever had cowpox will be immunized against smallpox (Davidson 29). “Edward Jenner was an English country doctor who introduced the vaccine for smallpox. Previously a keen practitioner of smallpox inoculation.”
Then, century after century, vaccine after vaccine was developed for different kinds of diseases. In the 20th century, one of the most known vaccines was Diphtheria and Tetanus vaccines. Diphtheria is a respiratory illness, causing the release of exotoxin from Corynebacterium diphtheriae bacteria which leads to death of mucus cells in the throat, mouth and nose, and as a result of cells accumulation the pseudo-membrane are build up and block the airways of the patients which causes death (Davidson 42) After years of experiments and trials to make a vaccine to fight this disease, Gaston Ramon a French veterinarian and biologist who realized that attenuated Diphtheria toxin is able to activate the immune system of people without causing serious side effects, and by 1927, the toxoid vaccine was freely used all around the world, and it succeeds to drop the number of cases of diphtheria. Then, by using the same way of toxoid, combined Diphtheria and Tetanus Toxoid vaccines were produced. Tetanus can be described as a nerves system infection that leads to spasm and contract of body muscles, especially jaw muscles which make the patients unable to open their mouths (Davidson. 44)
Another example of one of the most significant vaccine is a Polio vaccine. Polio disease, mainly affecting children under 5 years old, and leading to paralysis and often to death due to immobilization of respi.
Prospects for primary prevention of cervical cancer in developing countriesAlberto Cuadrado
The HPV types that cause cervical cancer are sexually transmitted,
but there is little evidence that infection can be avoided
by behavioural changes, such as condom use. In contrast,
prophylactic vaccines against HPV infection are likely to have
high efficacy. In principle, the effectiveness of HPV vaccination
as a strategy for cervical cancer control can be measured
either by monitoring secular trends in cervical cancer incidence
or by conducting randomized trials. The former approach
is unlikely to provide convincing evidence of effectiveness,
since cervical cancer rates are subject to strong secular
trends that are independent of intervention measures. A
few phase III trials of HPV prophylactic vaccines are now
being started. Such trials are very expensive studies involving
frequent and complicated investigations. It is important,
however, to start as soon as possible simpler trials designed
to demonstrate the effectiveness of HPV vaccine in field
conditions, i.e. in developing or intermediate countries which
suffer the major burden of mortality from cervical cancer.
Such trials may capture a difference in the most severe, and
rarest, preinvasive cervical lesions (i.e., the real target of
any HPV vaccine) over a prolonged follow-up (20 years at
least). The design of such studies is briefly considered for
two areas: Southern India and South Korea. This paper is
available at: http://www.insp.mx/salud/index.html
In this topic take about public health microbiology because of people are not aware about virus or disease vaccine is more essential for human being save our lives from the virus it is major requirements for people
Similar to PhRMA Report 2012: Vaccines in Development (20)
Prescription Medicines Costs in Context - June 2019PhRMA
We are in a new era of medicine where breakthrough science is transforming care with innovative treatment approaches and enabling us to more effectively treat chronic disease, the biggest cost driver.
Prescription Medicines - Insulin Costs in ContextPhRMA
A century ago, patients were treated with animal insulins. Today, biopharmaceutical companies produce insulins that operate at the molecular level, more closely resembling insulin released naturally in the body and more effectively managing the disease. The options available today also help meet a wide range of unmet needs, providing patients with the tools necessary to stay adherent and healthy – saving costs throughout the health care system. However, this innovation isn’t enough if patients can’t afford their insulin and other medicines at the pharmacy.
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Acute scrotum is a general term referring to an emergency condition affecting the contents or the wall of the scrotum.
There are a number of conditions that present acutely, predominantly with pain and/or swelling
A careful and detailed history and examination, and in some cases, investigations allow differentiation between these diagnoses. A prompt diagnosis is essential as the patient may require urgent surgical intervention
Testicular torsion refers to twisting of the spermatic cord, causing ischaemia of the testicle.
Testicular torsion results from inadequate fixation of the testis to the tunica vaginalis producing ischemia from reduced arterial inflow and venous outflow obstruction.
The prevalence of testicular torsion in adult patients hospitalized with acute scrotal pain is approximately 25 to 50 percent
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
PhRMA Report 2012: Vaccines in Development
1. 2012 Report
Medicines in Development
Vaccines
presented by america’s biopharmaceutical
research companies
Nearly 300 Vaccines Are in Development;
Research Focuses on Prevention and Treatment
Vaccines in Development*
170
For many years, vaccines have been used Today, biopharmaceutical research companies
to successfully prevent diseases such as are developing 295 vaccines. Potential vac-
smallpox, measles, polio and other infectious cines in development include:
diseases. A 2007 study by the U.S. Centers for • recombinant vaccine against malaria.
A
102
Disease Control and Prevention (CDC) found
that cases of vaccine-preventable diseases • vaccine that protects infants against
A
had reached an all-time low in the United meningococcal disease, a leading cause
of meningitis.
States. The study found that hospitalizations
and deaths from nine infectious diseases had • genetically-modified vaccine designed
A
declined by more than 90 percent and nearly for the treatment of pancreatic cancer.
90 percent for another four diseases. Although many new promising vaccines are
being researched today, the vaccine devel-
These findings illustrate the major contribution
opment process is not an easy one. As with
that vaccines have made in saving countless
the development of all drugs, vaccines must
lives around the world. In the past several
survive many years of thorough testing before
years, many successful new vaccines have
they can be approved for use by the general
been developed, including one against human
12 public. Advances in other scientific fields,
8 papillomavirus (HPV) infections that can lead
7
such as genomics, are becoming increasingly
to cervical cancer, one to guard against pre-
useful in the development of new vaccines.
exposure to the anthrax virus, and a vaccine to
With the continued efforts of researchers, it is
gy
es
r
s
er
he
er
prevent pneumococcal infections in high-risk
nc
ler
as
rd
Ot
likely that we may have many more vaccines
Ca
ise
Al
so
populations.
Di
sD
to protect against life-threatening diseases in
gic
u
tio
olo
ec
But vaccines are not only for preventing infec- the near future.
ur
Inf
Ne
tious diseases. In 2010, a new cancer vaccine
* Some vaccines are listed in for the treatment of prostate cancer was
more than one category. approved in the United States, and many more
are in development.
2. Medicines in Development for Vaccines
Allergy
Product Name Sponsor Indication Development Status*
cat allergy vaccine Greer Laboratories perennnial allergic rhinitis due to Phase I
sublingual Lenoir, NC cat hair (800) 419-7302
food allergy epicutaneous DBV Technologies peanut hypersensitivity Phase I
immunotherapy Bagneux, France (Fast Track) www.dbv-technologies.com
grass pollen allergy ALK Abello seasonal allergic rhinitis Phase III
vaccine tablet Horsholm, Denmark (800) 672-6372
(immunotherapy) Merck
Whitehouse Station, NJ
grass pollen extract Stallergenes seasonal allergic rhinitis Phase III
sublingual vaccine Norwell, MA (781) 878-0018
house dust mite allergy Greer Laboratories allergic rhinitis Phase I
sublingual vaccine Lenoir, NC (800) 419-7302
house dust mite allergy ALK Abello allergic asthma Phase II
vaccine tablet Horsholm, Denmark (800) 672-6372
Merck
Whitehouse Station, NJ
peanut allergy vaccine Allertein Therapeutics peanut hypersensitivity Phase I
Fairfield, CT
Pollinex® Quattro Allergy Therapeutics prevention of grass pollen Phase III
injectable MPL allergy vaccine West Sussex, United Kingdom hypersensitivity, prevention of www.allergytherapeutics.com
ragweed hypersensitivity
-------------------------------------------------- -------------------------------------------
prevention of tree pollen Phase II
hypersensitivity www.allergytherapeutics.com
QGE031 Novartis Pharmaceuticals allergic diseases Phase I
(anti-IgE antibody) East Hanover, NJ (888) 669-6682
ragweed allergy immunotherapy Stallergenes seasonal allergic rhinitis Phase I
vaccine Norwell, MA (781) 878-0018
ragweed allergy vaccine Greer Laboratories seasonal allergic rhinitis Phase III
sublingual Lenoir, NC (800) 419-7302
ragweed allergy vaccine ALK Abello seasonal allergic rhinitis Phase III
sublingual tablet Horsholm, Denmark (800) 672-6372
Merck
Whitehouse Station, NJ
* For more information about a specific medicine in this report, please call the telephone number listed.
2 Medicines in Development Vaccines 2012
3. Medicines in Development for Vaccines
Cancer
Product Name Sponsor Indication Development Status
abagovomab Menarini ovarian cancer Phase III
(anti-idiotype mAb vaccine) Florence, Italy www.menarini.com
ADXS-HPV Advaxis recurrent cervical cancer, cervical Phase II
(live, attenuated Listeria Princeton, NJ intraepithelial neoplasia (609) 452-9813
monocytogenes [Lm]-based
vaccine)
AE37 Antigen Express breast cancer Phase II
(peptide vaccine) Worcester, MA (508) 852-8783
-------------------------------------------------- -------------------------------------------
ovarian cancer (combination Phase I
therapy), prostate cancer (508) 852-8783
AGS-003 Argos Therapeutics kidney cancer (combination therapy), Phase II
(personalized dendritic Durham, NC metastatic kidney cancer (919) 287-6300
cell-based immunotherapy) (monotherapy)
AlloStim™ Novo Energies hematological malignancies, Phase I/II
immunotherapeutic vaccine Montreal, Canada solid tumors (514) 840-3697
anti-GnRH vaccine Novartis Vaccines Diagnostics prostate cancer Phase I/II
Cambridge, MA (617) 871-7000
Pepscan Therapeutics
Lelystad, Netherlands
astuprotimut-R GlaxoSmithKline malignant melanoma, non-small-cell Phase III
(MAGE-A3 recombinant Rsch. Triangle Park, NC lung cancer (NSCLC) (888) 825-5249
antigen-specific cancer -------------------------------------------------- -------------------------------------------
immunotherapy) bladder cancer Phase II
(888) 825-5249
AVX-701 AlphaVax prevention of advanced or metastatic Phase I/II
Rsch. Triangle Park, NC CEA-expressing colorectal cancer (919) 595-0400
B7-2/GM-CSF NuVax Therapeutics cancer Phase I
cancer gene therapy vaccine Tustin, CA (714) 505-4461
BiovaxID® Biovest International indolent follicular lymphoma Phase III
B-cell lymphoma vaccine Tampa, FL (Fast Track) (813) 864-2558
(personalized lymphoma -------------------------------------------------- -------------------------------------------
vaccine) mantle-cell lymphoma Phase II
(813) 864-2558
BPX-101 Bellicum Pharmaceuticals prostate cancer Phase I/II
(dendritic cell vaccine) Houston, TX www.bellicum.com
breast cancer vaccine Quantum Immunologics breast cancer Phase I/II
(dendritic cell vaccine) Tampa, FL (813) 849-7885
Medicines in Development Vaccines 2012 3
4. Medicines in Development for Vaccines
Cancer
Product Name Sponsor Indication Development Status
cancer vaccine Immunovaccine ovarian cancer Phase I
Halifax, Canada (902) 492-1819
cancer vaccine Activartis Biotech glioblastoma (first-line therapy) Phase II
(autologous dendritic cell Vienna, Austria www.activartis.com
vaccine) -------------------------------------------------- -------------------------------------------
metastatic renal cancer in clinical trials
www.activartis.com
cancer vaccine Bayer HealthCare Pharmaceuticals follicular lymphoma (prevention of Phase I
(autologous idiotype vaccine) Wayne, NJ relapse) (888) 842-2937
cancer vaccine Cytokine PharmaSciences cancer Phase I
(fibrocyte vaccine) King of Prussia, PA (610) 687-1776
cancer vaccine MabVax Therapeutics sarcoma Phase II
(mAb vaccine) San Diego, CA (858) 259-9405
-------------------------------------------------- -------------------------------------------
breast cancer Phase I
(858) 259-9405
CB-10-01 Cosmo Pharmaceuticals malignant melanoma Phase II
Lainate, Italy www.cosmopharmaceuticals.
com
CDX-1401 Celldex Therapeutics solid tumors expressing the Phase I/II
Needham, MA NY-ESO-1 protein (781) 433-0771
CG201 CG Therapeutics solid tumors Phase II
Seattle, WA (206) 336-5604
CLL MaxCyte chronic lymphocytic leukemia (CLL) Phase I/II
immunotherapeutic Gaithersburg, MD (301) 944-1700
CRS-207 Aduro BioTech metastatic pancreatic cancer Phase II
Berkeley, CA (combination therapy) (510) 848-4400
CV-301 BN ImmunoTherapeutics metastatic breast cancer Phase II
(immunotherapeutic vaccine) (Bavarian Nordic) (650) 681-4660
Mountain View, CA
CVac™ Prima Biomed ovarian cancer Phase II/III
cancer vaccine Sydney, Australia www.primabiomed.com.au
MUC-1
4 Medicines in Development Vaccines 2012
5. Medicines in Development for Vaccines
Cancer
Product Name Sponsor Indication Development Status
DCVax®-Brain Northwest Biotherapeutics glioblastoma Phase II
dendritic cell-based vaccine Bethesda, MD (240) 497-9024
(Orphan Drug)
DCVax®-Ovarian Northwest Biotherapeutics ovarian cancer, peritoneal cancer Phase I
dendritic cell-based vaccine Bethesda, MD (240) 497-9024
DCVax®-Prostate Northwest BioTherapeutics prostate cancer Phase III
dendritic cell-based vaccine Bethesda, MD (240) 497-9024
dendritic cell cancer vaccine EMD Serono malignant melanoma Phase I
Rockland, MA (800) 283-8088
DN24-02 Dendreon HER2-positive urogenital cancer Phase II
(lapuleucel-T) Seattle, WA (adjuvant therapy) (877) 256-4545
(dendritic cell vaccine) -------------------------------------------------- -------------------------------------------
breast cancer, colorectal cancer, Phase I completed
ovarian cancer (877) 256-445
DPX-0907 Immunovaccine breast cancer, ovarian cancer, Phase I
Halifax, Canada prostate cancer (902) 492-1819
EC17 Endocyte kidney cancer Phase I
West Lafayette, IN (combination therapy) www.endocyte.com
ETBX-011 Etubics solid tumors Phase I
(adenovirus vector vaccine) Seattle, WA (206) 838-5110
FANG™ vaccine Gradalis malignant melanoma, ovarian cancer Phase II
(autologous tumor cell vaccine) Carrollton, TX (214) 442-8100
FBP vaccine Galena Biopharma endometrial cancer, ovarian cancer Phase I/II
(folate-binding protein Lake Oswego, OR (855) 855-4253
E39 vaccine) -------------------------------------------------- -------------------------------------------
breast cancer Phase I
(855) 855-4253
G-100 prophage cancer vaccine Agenus newly-diagnosed glioma Phase II
(Orphan Drug) Lexington, MA (781) 674-4400
G-200 prophage cancer vaccine Agenus recurrent glioma Phase II
(Orphan Drug) Lexington, MA (781) 674-4400
Medicines in Development Vaccines 2012 5
6. Medicines in Development for Vaccines
Cancer
Product Name Sponsor Indication Development Status
GI-4000 GlobeImmune colorectal cancer, pancreatic cancer Phase II
(therapeutic vaccine) Louisville, CO (303) 625-2700
-------------------------------------------------- -------------------------------------------
colorectal cancer (first-line therapy), Phase I
colorectal cancer (second-line (303) 625-2700
therapy), NSCLC
GI-6207 GlobeImmune metastatic cancer Phase I
(therapeutic vaccine) Louisville, CO (303) 625-2700
GI-6301 GlobeImmune solid tumors Phase I
(brachyury peptide vaccine) Louisville, CO (303) 625-2700
GRNVAC1 Geron acute myeloid leukemia (AML) Phase II
(telomerase-based cancer Menlo Park, CA (650) 473-7700
vaccine) -------------------------------------------------- -------------------------------------------
prostate cancer Phase I/II
(650) 473-7700
GSK2241658A GlaxoSmithKline metastatic melanoma Phase I
(NY-ESO-1 antigen-specific Rsch. Triangle Park, NC (888) 825-5249
cancer immunotherapeutic)
GV1001 KAEL-GemVax pancreatic cancer Phase I
(hTERT RNA vaccine) Seoul, South Korea www.kaelgemvax.com
(Orphan Drug)
GVAX® Breast BioSante Pharmaceuticals breast cancer Phase I
immunotherapeutic vaccine Lincolnshire, IL (847) 478-0500
GVAX® Colorectal BioSante Pharmaceuticals colorectal cancer Phase I
immunotherapeutic vaccine Lincolnshire, IL (847) 478-0500
GVAX® Leukemia BioSante Pharmaceuticals AML, chronic myeloid leukemia Phase II
immunotherapeutic vaccine Lincolnshire, IL (CML) (847) 478-0500
(Orphan Drug)
GVAX® Myeloma BioSante Pharmaceuticals multiple myeloma Phase II
immunotherapeutic vaccine Lincolnshire, IL (847) 478-0500
GVAX® Pancreatic BioSante Pharmaceuticals pancreatic cancer Phase II
immunotherapeutic vaccine Lincolnshire, IL (847) 478-0500
(Orphan Drug)
GVAX® Prostate BioSante Pharmaceuticals prostate cancer Phase III
immunotherapeutic vaccine Lincolnshire, IL (Fast Track) (847) 478-0500
6 Medicines in Development Vaccines 2012
7. Medicines in Development for Vaccines
Cancer
Product Name Sponsor Indication Development Status
HS-110 Heat Biologics NSCLC (combination therapy) Phase II
Chapel Hill, NC (919) 240-7133
hTERT vaccine Merck cancer Phase I
(human telomerase reverse Whitehouse Station, NJ (800) 672-6372
transcriptase cancer vaccine) Vical (858) 646-1100
San Diego, CA
HyperAcute® Lung NewLink Genetics NSCLC Phase II
lung cancer immunotherapy Ames, IA (515) 296-5555
HyperAcute® Melanoma NewLink Genetics malignant melanoma Phase II
lung cancer immunotherapy Ames, IA (515) 296-5555
HyperAcute® Pancreas NewLink Genetics pancreatic cancer Phase III
algenpantucel-L Ames, IA (Fast Track) (515) 296-5555
(Orphan Drug)
ICT-107 ImmunoCellular Therapeutics glioblastoma Phase II
(autologous dendritic-cell Woodland Hills, CA (818) 992-2907
vaccine)
(Orphan Drug)
IDM-2101 Biotech Synergy NSCLC Phase II
(multi-epitope cancer vaccine) San Diego, CA (858) 459-6689
IMA901 immatics biotechnologies kidney cancer Phase III
(multiple tumor-associated Tuebingen, Germany www.immatics.com
peptides cancer vaccine)
IMCgp100 Immunocore malignant melanoma Phase 0
Oxon, United Kingdom www.immunocore.com
IMF-001 ImmunoFrontier solid tumors Phase I
(protein vaccine) Tokyo, Japan www.immunofrontier.com
IMT-1012 Immunotope breast cancer, ovarian cancer Phase I
(multi-peptide antigen Doylestown, PA (215) 253-4180
immunotherapeutics vaccine)
ISF35 Memgen CLL (monotherapy), Phase II
(recombinant immunotherapy) San Diego, CA non-Hodgkin’s lymphoma (858) 524-5400
-------------------------------------------------- -------------------------------------------
CLL (combination therapy) Phase I
(858) 524-5400
Medicines in Development Vaccines 2012 7
8. Medicines in Development for Vaccines
Cancer
Product Name Sponsor Indication Development Status
JVRS-100 Colby Pharmaceutical leukemia Phase I
(lipid-DNA complex vaccine) San Jose, CA (650) 333-3152
Lucanix® NovaRx NSCLC Phase III
belagenpumatucel-L San Diego, CA (Fast Track) (858) 552-8600
(cell-based therapeutic vaccine) -------------------------------------------------- -------------------------------------------
glioma Phase I
(858) 552-8600
LungVax® AVAX Technologies NSCLC Phase I/II
autologous cell vaccine Philadelphia, PA (215) 241-9760
M-200 prophage cancer vaccine Agenus metastatic melanoma Phase III
(Orphan Drug) Lexington, MA (Fast Track) (781) 674-4400
melanoma DNA vaccine Ichor Medical Systems malignant melanoma Phase I
San Diego, CA (858) 550-2022
Memorial Sloan-Kettering Cancer
Center
New York, NY
MVA-BN® Breast BN ImmunoTherapeutics breast cancer Phase I
HER-2/neu-based modified (Bavarian Nordic) (650) 681-4660
vaccinia ankara (MVA) vaccine Mountain View, CA
MVA-BN®-PRO BN ImmunoTherapeutics prostate cancer Phase I/II
(Bavarian Nordic) (650) 681-4660
Mountain View, CA
MVax® AVAX Technologies malignant melanoma Phase III
autologous cell vaccine Philadelphia, PA (215) 241-9760
NeuVax™ Galena Biopharma early-stage breast cancer Phase III
E75 cancer vaccine Lake Oswego, OR (prevention of relapse) (855) 855-4253
-------------------------------------------------- -------------------------------------------
prostate cancer Phase I/II
(855) 855-4253
Oncophage® Agenus renal cell carcinoma Phase II
vitespen Lexington, MA (Fast Track) (781) 674-4400
(Orphan Drug)
OncoVAX® Vaccinogen stage III colorectal cancer Phase II
colorectal cancer vaccine Frederick, MD (combination therapy) (301) 668-8400
-------------------------------------------------- -------------------------------------------
colorectal cancer Phase I/II
(Fast Track) (301) 668-8400
ONT-10 Oncothyreon solid tumors Phase I
Seattle, WA (206) 801-2100
8 Medicines in Development Vaccines 2012
9. Medicines in Development for Vaccines
Cancer
Product Name Sponsor Indication Development Status
OPT-822 Optimer Pharmaceuticals breast cancer Phase II
San Diego, CA (858) 909-0736
oral peptide cancer vaccine Immunitor cancer Phase I/II
Vancouver, Canada
oregovomab Quest PharmaTech ovarian cancer Phase I/II
(Orphan Drug) Edmonton, Canada (780) 448-1400
OVax® AVAX Technologies ovarian cancer Phase I/II
autologous tumor cell vaccine Philadelphia, PA (215) 241-9760
(Orphan Drug)
POL-103A Polynoma malignant melanoma Phase II
(polyvalent shed-antigen San Diego, CA (858) 205-2501
vaccine)
(Orphan Drug)
polyclonal antibody stimulator Cancer Advances gastric cancer, pancreatic cancer Phase III
(Orphan Drug) Durham. NC (see also other) (919) 361-2162
-------------------------------------------------- -------------------------------------------
colorectal cancer Phase II
(919) 361-2162
PRAME GlaxoSmithKline metastatic melanoma, NSCLC Phase I
antigen-specific cancer Rsch. Triangle Park, NC (888) 825-5249
immunotherapeutic
Prostvac™ BN ImmunoTherapeutics metastatic prostate cancer Phase III
prostate cancer vaccine (Bavarian Nordic) (Fast Track) (650) 681-4660
Mountain View, CA
Provenge® Dendreon recurrent early-stage prostate cancer Phase III
sipuleucel-T Seattle, WA (877) 256-4545
-------------------------------------------------- -------------------------------------------
early-stage prostate cancer Phase II
(neoadjuvant therapy) (877) 256-4545
PSMA VRP therapeutic vaccine Progenics Pharmaceuticals prostate cancer Phase I
Tarrytown, NY (914) 789-2800
PT107 Pique Therapeutics NSCLC Phase II
(allogeneic tumor cell vaccine) Durham, NC (919) 806-4395
recombinant soluble PSMA Progenics Pharmaceuticals prostate cancer Phase I
protein vaccine Tarrytown, NY (914) 789-2800
Medicines in Development Vaccines 2012 9
10. Medicines in Development for Vaccines
Cancer
Product Name Sponsor Indication Development Status
REIC gene therapy Momotaro-Gene prostate cancer Phase I
Okayama, Japan www.mt-gene.com
Reximmune-C® Epeius Biotechnologies breast cancer Phase I/II
personalized cancer vaccine San Marino, CA (626) 441-6695
rindopepimut Celldex Therapeutics glioblastoma (first-line therapy) Phase III
(Orphan Drug) Needham, MA (Fast Track) (781) 433-0771
-------------------------------------------------- -------------------------------------------
glioblastoma (combination therapy, Phase II
second-line therapy) (781) 433-0771
(Fast Track)
SL-701 Stemline Therapeutics glioma Phase I/II
(dendritic cell vaccine) New York, NY (212) 831-1111
Stimuvax® EMD Serono NSCLC (Fast Track) Phase III
emepepimut-S Rockland, MA (800) 283-8088
Oncothyreon -------------------------------------------------- (206) 769-9219
Seattle, WA prostate cancer -------------------------------------------
Phase II
(800) 283-8088
(206) 769-9219
TAG vaccine Gradalis solid tumors Phase I
Carrollton, TX (214) 442-8100
TeloB-Vax Adamis Pharmaceuticals prostate cancer Phase I
telomerase cancer vaccine San Diego, CA www.adamispharma.com
tipapkinogene sovacivec Transgene cervical intraepithelial neoplasia Phase II
Rockville, MD (301) 816-5421
TroVax® Oxford BioMedica hormone refractory prostate cancer Phase II
tumor-associated antigen Oxford, United Kingdom www.oxfordbiomedica.co.uk
vaccine
TVI-Brain-1 TVAX Biomedical glioma Phase II
(cellular immunotherapy Lenexa, KS (913) 492-2221
vaccine)
TVI-Kidney-1 TVAX Biomedical renal cell carcinoma in clinical trials
(cellular immunotherapy Lenexa, KS (913) 492-2221
vaccine)
V503 Merck prevention of cervical cancer, Phase III
(virus-like particle [VLP] Whitehouse Station, NJ prevention of vulvovaginal cancer (800) 672-6372
vaccine) (see also infectious diseases)
10 Medicines in Development Vaccines 2012
11. Medicines in Development for Vaccines
Cancer
Product Name Sponsor Indication Development Status
V505 Merck prevention of cervical cancer Phase II completed
Whitehouse Station, NJ (see also infectious diseases) (800) 672-6372
V930/V932 Merck cancer Phase I
(plasmid DNA cancer vaccine) Whitehouse Station, NJ (800) 672-6372
Vical (858) 646-1100
San Diego, CA
V935 Geron solid tumors Phase I
(telomerase inhibitor vaccine) Menlo Park, CA (650) 473-7700
Merck (800) 672-6372
Whitehouse Station, NJ
verpasep caltespen Akela Pharma cervical intraepithelial neoplasia Phase I completed
Austin, TX (512) 834-0449
VGX-3100 Inovio Pharmaceuticals cervical intraepithelial neoplasia Phase II
Blue Bell, PA (see also infectious diseases) (877) 446-6846
WT1 antigen specific cancer GlaxoSmithKline AML Phase II
immunotherapeutic Rsch. Triangle Park, NC (888) 825-5249
-------------------------------------------------- -------------------------------------------
breast cancer Phase I
(888) 825-5249
Infectious Diseases
Product Name Sponsor Indication Development Status
ACAM-Cdiff sanofi pasteur Clostridium difficile infections Phase II
(toxoid vaccine) Swiftwater, PA (800) 822-2463
ACE527 ACE Biosciences prevention of traveler’s diarrhea Phase II
(oral pentavalent vaccine) Odense, Denmark caused by Escherichia coli infections www.acebiosciences.com
TD Vaccines www.tdvaccines.com
Skorping, Denmark
Ad26.ENVA.01 Crucell prevention of HIV infection Phase I
HIV-1 recombinant vaccine Leiden, Netherlands www.crucell.com
ADVAX Aaron Diamond AIDS Research HIV infection prevention Phase I completed
(DNA vaccine) Center (212) 448-5000
New York, NY (212) 847-1111
International AIDS Vaccine Initiative -------------------------------------------------- -------------------------------------------
New York, NY HIV infection prevention Phase I completed
Ichor Medical Systems (new delivery system) (212) 448-5000
San Diego, CA (212) 847-1111
Medicines in Development Vaccines 2012 11
12. Medicines in Development for Vaccines
Infectious Diseases
Product Name Sponsor Indication Development Status
Aflunov™ Novartis Vaccines Diagnostics prevention of influenza A virus H5N1 Phase II
influenza A virus H5N1 vaccine Cambridge, MA subtype (pre-pandemic) (617) 871-7000
AG-707 Agenus treatment of herpes simplex virus Phase I completed
(herpes simplex vaccine) Lexington, MA infections (781) 674-4400
AGS-004 Argos Therapeutics HIV-1 infection Phase II
(personalized dendritic Durham, NC (919) 287-6300
cell-based immunotherapy)
anthrax transdermal vaccine Intercell USA anthrax Phase I
Gaithersburg, MD (301) 556-4500
ANZ-521 Aduro BioTech treatment of hepatitis C Phase I
(recombinant vaccine) Berkeley, CA (510) 848-4400
AV-7909 Emergent BioSolutions anthrax Phase I
(anthrax vaccine adsorbed with Rockville, MD (301) 795-1800
adjuvant)
AVX-101 AlphaVax prevention of HIV-1 infection Phase I completed
(monovalent HIV vaccine) Rsch. Triangle Park, NC (919) 595-0400
AVX-502 AlphaVax prevention of influenza virus Phase I/II
Rsch. Triangle Park, NC infections in the elderly (919) 595-0400
BioThrax® Emergent BioSolutions anthrax (post-exposure prevention) Phase III
anthrax vaccine adsorbed Rockville, MD (Fast Track) (301) 795-1800
botulinum toxin recombinant DynPort Vaccine Company botulism Phase II
vaccine Frederick, MD (301) 607-5000
chikungunya virus vaccine Inviragen chikungunya virus infections Phase II
Fort Collins, CO (970) 672-4918
CholeraGarde® Vaccine Technologies cholera Phase II
cholera vaccine live attenuated Boston, MA (617) 358-5011
ChronVac-C® Inovio Pharmaceuticals treatment of hepatitis C Phase II
hepatitis C DNA vaccine Blue Bell, PA (877) 446-6846
ChronTech Pharma
Huddinge, Sweden
cytomegalovirus vaccine AlphaVax prevention of cytomegalovirus Phase I
(AVX-601) Rsch. Triangle Park, NC infections (617) 871-7000
Novartis Vaccines Diagnostics
Cambridge, MA
12 Medicines in Development Vaccines 2012
13. Medicines in Development for Vaccines
Infectious Diseases
Product Name Sponsor Indication Development Status
DCVax-001 Celldex Therapeutics prevention and treatment of HIV Phase I
(recombinant protein vaccine) Needham, MA infection (781) 433-0771
dengue DNA vaccine U.S. Naval Medical Research Center prevention of dengue fever Phase I
Silver Spring, MD (858) 646-1100
Vical
San Diego, CA
dengue fever vaccine GlaxoSmithKline prevention of dengue fever Phase II completed
Rsch. Triangle Park, NC (888) 825-5249
dengue fever vaccine sanofi pasteur prevention of mild to severe dengue Phase III
Swiftwater, PA fever (800) 822-2463
(Fast Track)
DENVax™ Inviragen dengue Phase I
tetravalent hybrid dengue virus Fort Collins, CO (970) 672-4918
vaccine
DermaVir™ Patch Genetic Immunity treatment of HIV-1 infection Phase II
DNA topical patch vaccine McLean, VA (703) 879-6803
DTP-HepB-Polio-Hib Merck diphtheria, tetanus, pertussis, Phase III
hexavalent vaccine Whitehouse Station, NJ hepatitis B, poliomyelitis, (800) 672-6372
sanofi pasteur Haemophilus influenzae type b (800) 822-2463
Swiftwater, PA (infants)
DV-601 Dynavax treatment of hepatitis B Phase I
(therapeutic vaccine) Berkeley, CA (510) 848-5100
Ebola vaccine Crucell prevention of Ebola virus infections Phase I
Leiden, Netherlands www.crucell.com
Vaccine Research Center (NIAID)
Bethesda, MD
Ebola virus vaccine GenPhar Ebola virus infections in clinical trials
Mt. Pleasant, SC (843) 884-0120
EP1043 VaxOnco prevention of HIV-1 infections Phase I
(recombinant protein vaccine) Seoul, South Korea www.vaxonco.com
National Institute of Allergy and
Infectious Diseases
Bethesda, MD
EP1090 VaxOnco prevention and treatment of HIV-1 Phase I/II
(DNA vaccine) Seoul, South Korea infections www.vaxonco.com
National Institute of Allergy and
Infectious Diseases
Bethesda, MD
Medicines in Development Vaccines 2012 13
14. Medicines in Development for Vaccines
Infectious Diseases
Product Name Sponsor Indication Development Status
EP1300 VaxOnco prevention of malaria Phase I
(DNA vaccine) Seoul, South Korea www.vaxonco.com
National Institutes of Health
Bethesda, MD
ETEC vaccine Vaccine Technologies prevention of cholera, Escherichia Phase I
Boston, MA coli infections (617) 358-5011
FluBlok® Protein Sciences prevention of influenza virus application submitted
influenza virus vaccine Meridian, CT infections (adults and children) (800) 488-7099
(Fast Track)
FluLaval™ GlaxoSmithKline prevention of influenza virus Phase III completed
influenza virus vaccine Rsch. Triangle Park, NC infections (888) 825-5249
(pediatric)
Fluvirin® Novartis Vaccines Diagnostics prevention of influenza A virus H1N1 Phase II/III completed
influenza A virus H1N1 vaccine Cambridge, MA subtype (pediatric) (617) 871-7000
Fluzone® QIV IM sanofi pasteur influenza virus infections Phase III
quadrivalent inactivated influ- Swiftwater, PA (800) 822-2463
enza vaccine
GelVac™ Nanotherapeutics influenza virus infections Phase I
H5N1 influenza virus vaccine Alachua, FL (386) 462-9663
intranasal
GI-5005 GlobeImmune hepatitis C (combination therapy) Phase II
(therapeutic vaccine) Louisville, CO (303) 625-2700
GSK1437173A GlaxoSmithKline prevention of varicella zoster virus Phase III
(varicella zoster vaccine) Rsch. Triangle Park, NC infections (888) 825-5249
GSK1492903A GlaxoSmithKline prevention of cytomegalovirus Phase I
(recombinant glycoprotein Rsch. Triangle Park, NC infections (888) 825-5249
vaccine)
GSK2189242A GlaxoSmithKline prevention of pneumococcal Phase II
(Streptococcus pneumoniae Rsch. Triangle Park, NC infections (888) 825-5249
recombinant conjugated
vaccine)
GSK2254232A GlaxoSmithKline prevention of Haemophilus Phase I completed
(Haemophilus influenzae, Rsch. Triangle Park, NC infections, prevention of (888) 825-5249
pneumococcal recombinant pneumococcal infections
vaccine)
14 Medicines in Development Vaccines 2012
15. Medicines in Development for Vaccines
Infectious Diseases
Product Name Sponsor Indication Development Status
GSK2254233A GlaxoSmithKline prevention of Haemophilus Phase I completed
(Haemophilus influenzae, Rsch. Triangle Park, NC infections, prevention of (888) 825-5249
pneumococcal recombinant pneumococcal infections
vaccine)
GSK2282512A GlaxoSmithKline prevention of influenza virus application submitted
(influenza virus vaccine) Rsch. Triangle Park, NC infections (adults, adolescents and (888) 825-5249
children)
GSK2321138A GlaxoSmithKline prevention of influenza virus application submitted
(influenza virus vaccine) Rsch. Triangle Park, NC infections (adults, adolescents and (888) 825-5249
children)
GSK2340273A GlaxoSmithKline prevention of influenza A virus Phase II
(influenza A virus Rsch. Triangle Park, NC H1N1 subtype (children and infants) (888) 825-5249
H1N1 vaccine)
GSK2340274A GlaxoSmithKline prevention of influenza A virus H1N1 Phase II
(influenza A virus vaccine) Rsch. Triangle Park, NC subtype (children and infants) (888) 825-5249
-------------------------------------------------- -------------------------------------------
influenza A virus H5N1 subtype Phase I
(888) 825-5249
GSK2392102A GlaxoSmithKline staphylococcal infections Phase I
(Staphylococcus aureus Rsch. Triangle Park, NC (888) 825-5249
vaccine)
GSK2830930A GlaxoSmithKline pneumococcal infections Phase I
(pneumococcal vaccine) Rsch. Triangle Park, NC (888) 825-5249
H5N1 influenza virus vaccine Novavax prevention of influenza A virus H5N1 Phase II
(recombinant) Rockville, MD subtype (240) 268-2000
H5N1 influenza virus vaccine Vaxart prevention of influenza A virus H5N1 Phase I
San Francisco, CA subtype (415) 437-0132
H5N1 pandemic influenza virus GlaxoSmithKline prevention of influenza A virus H5N1 application submitted
vaccine Rsch. Triangle Park, NC subtype (888) 825-5249
-------------------------------------------------- -------------------------------------------
prevention of influenza A virus H5N1 Phase III
subtype (children and adolescents) (888) 825-5249
HBV-002 Hawaii Biotech prevention of West Nile virus Phase I completed
(recombinant subunit vaccine) Aiea, HI infection (808) 486-5333
Helicobacter pylori vaccine Novartis Vaccines Diagnostics helicobacter infections Phase I
Cambridge, MA (617) 871-7000
Medicines in Development Vaccines 2012 15
16. Medicines in Development for Vaccines
Infectious Diseases
Product Name Sponsor Indication Development Status
hepatitis B DNA vaccine Pfizer hepatitis B Phase I
New York, NY (860) 732-5156
hepatitis B vaccine Emergent BioSolutions hepatitis B Phase II
Rockville, MD (301) 795-1800
hepatitis C vaccine Okairos prevention of hepatitis C Phase I/II
Rome, Italy www.okairos.il
hepatitis C vaccine Novartis Vaccines Diagnostics treatment of hepatitis C Phase I/II
(HCV/MF59) Cambridge, MA (617) 871-7000
Heplisav™ Dynavax prevention of hepatitis B Phase III
hepatitis B vaccine 1018-ISS Berkeley, CA (510) 848-5100
conjugate
herpes simplex DNA vaccine Pfizer treatment of herpes simplex virus Phase I
New York, NY infections (860) 732-5156
herpes simplex vaccine AuRx prevention and treatment of herpes Phase I/II
Elkridge, MD (410) 796-759
Hexaxim® sanofi pasteur diptheria, tetanus, pertussis, application submitted
DTP-HepB-Polio-Hib vaccine Swiftwater, PA hepatitis B, poliomyelitis, (800) 822-2463
Haemophilus influenzae type b
(infants)
HIVAX™ GeneCure Biotechnologies HIV-1 infection Phase I
replication-defective HIV-1 Norcross, GA (770) 263-7508
vaccine
HIV recombinant vaccine GlaxoSmithKline treatment of HIV infection Phase II
(gag/pol/nef) Rsch. Triangle Park, NC (888) 825-5249
HIV recombinant vaccine GlaxoSmithKline prevention of HIV-1 infection Phase I completed
(gp120/NefTat/AS02A) Rsch. Triangle Park, NC (888) 825-5249
HIV vaccine GeoVax Labs prevention of HIV infection Phase II
Smyrna, GA (678) 384-7220
HIV vaccine GeoVax Labs treatment of HIV infection Phase I/II
Smyrna, GA (678) 384-7220
HIV vaccine Novartis Vaccines Diagnostics HIV infection Phase I
Cambridge, MA (617) 871-7000
16 Medicines in Development Vaccines 2012
17. Medicines in Development for Vaccines
Infectious Diseases
Product Name Sponsor Indication Development Status
HIV vaccine Opal Therapeutics HIV infection Phase I
Palo Alto, CA (617) 726-2000
Massachusetts General Hospital
Boston, MA
HIV vaccine Profectus Biosciences prevention of HIV infection Phase I
(MAG pDNA) Baltimore, MD (866) 938-8559
HIV vaccine Profectus Biosciences prevention of HIV infection Phase I
(rVSV) Baltimore, MD (866) 938-8559
Imvamune® BM ImmunoTherapeutics smallpox Phase II
smallpox vaccine (Bavarian Nordic) (650) 681-4660
Mountain View, CA
influenza A virus H1N1 vaccine CEL-SCI prevention and treatment of influenza Phase I
Vienna, VA A virus H1N1 subtype (703) 506-9460
influenza A virus H1N1 vaccine iBio prevention of influenza A virus H1N1 Phase I
Newark, DE subtype www.ibioinc.com
Fraunhofer USA Center for
Molecular Biotechnology
Newark, DE
influenza A virus H5N1 GlaxoSmithKline prevention of influenza A virus H5N1 Phase I
cell culture-based vaccine Rsch. Triangle Park, NC subtype (pandemic use) (888) 825-5249
influenza A virus H5N1 vaccine Baxter Healthcare prevention of influenza A virus H5N1 Phase I
Deerfield, IL subtype (800) 422-9837
influenza A virus vaccine H1N1 Medicago USA prevention of influenza A virus H1N1 Phase I
Durham, NC subtype (919) 313-9670
influenza A virus vaccine H5N1 iBio prevention of influenza A virus H5N1 Phase I
Newark, DE subtype www.ibioinc.com
influenza A virus vaccine H9N2 Baxter Healthcare prevention of influenza A virus H9N2 Phase I/II
Deerfield, IL subtype (800) 422-9837
influenza virus DNA vaccine Vical prevention of influenza A virus H1N1 Phase I completed
San Diego, CA subtype (858) 646-1100
influenza virus vaccine Dynavax prevention of influenza virus Phase I
Berkeley, CA infections (510) 848-5100
influenza virus vaccine Novartis Vaccines Diagnostics influenza virus infections Phase III
(Fluad) Cambridge, MA (children and elderly) (617) 871-7000
Medicines in Development Vaccines 2012 17
18. Medicines in Development for Vaccines
Infectious Diseases
Product Name Sponsor Indication Development Status
influenza virus vaccine Vaxin influenza virus infections Phase I
intranasal Birmingham, AL (205) 413-8238
Influvac® TC Abbott Laboratories prevention of influenza virus Phase I
cell culture-derived influenza Abbott Park, IL infections (847) 937-6100
vaccine
INO-3510 Inovio Pharmaceuticals influenza A virus H1N1 subtype, Phase I
(DNA vaccine) Blue Bell, PA influenza A virus H5N1 subtype (877) 466-6846
Ixiaro® Intercell prevention of Japanese encephalitis Phase III
Japanese encephalitis vaccine Vienna, Austria (pediatric) (617) 871-7000
Novartis Vaccines Diagnostics
Cambridge, MA
Ii-Key hybrid peptide vaccine Antigen Express influenza A virus H1N1 subtype Phase I
Worcester, MA (508) 852-8783
LIQ-001 Liquidia Technologies influenza virus infections Phase I
Rsch. Triangle Park, NC (919) 328-4400
Lyme disease vaccine Bayer HealthCare Pharmaceuticals prevention of Lyme disease Phase I/II
Wayne, NJ (888) 842-2937
malaria DNA vaccine U.S. Naval Medical Research Center malaria Phase I/II
Silver Spring, MD (858) 646-1100
Vical
San Diego, CA
malaria vaccine GenVec malaria Phase I/II
Gaithersburg, MD (877) 943-6832
U.S. Naval Medical Research Center
Silver Spring, MD
malaria vaccine Sanaria malaria Phase I/II
Rockville, MD (301) 770-3222
malaria vaccine Crucell malaria Phase I
(recombinant) Leiden, Netherlands www.crucell.com
malaria vaccine Crucell prevention of malaria Phase I/II
(recombinant combination Leiden, Netherlands www.crucell.com
vaccine) GlaxoSmithKline (888) 825-5249
Rsch. Triangle Park, NC
Marburg virus DNA vaccine GenPhar Marburg virus disease in clinical trials
Mt. Pleasant, SC (843) 884-0120
MEDI-534 MedImmune prevention of parainfluenza and Phase I
(RSV/PIV-3 vaccine) Gaithersburg, MD respiratory syncytial virus infections (301) 398-0000
18 Medicines in Development Vaccines 2012
19. Medicines in Development for Vaccines
Infectious Diseases
Product Name Sponsor Indication Development Status
MEDI-550 MedImmune prevention of pandemic influenza Phase I
(pandemic influenza virus Gaithersburg, MD (H5N1 subtype) (301) 398-0000
vaccine)
MEDI-559 MedImmune prevention of respiratory syncytial Phase I
(RSV vaccine) Gaithersburg, MD virus infections (pediatric) (301) 398-0000
MenABCWY Novartis Vaccine Diagnostics prevention of meningococcal groups Phase II
(multivalent conjugate vaccine) Cambridge, MA A, B, C, Y and W-135 infections (617) 871-7000
(adolescents)
MenHibrix® GlaxoSmithKline prevention of Neisseria meningitidis application submitted
Hib-MenCY-TT conjugated Rsch. Triangle Park, NC groups C and Y infections and (888) 825-5249
vaccine Haemophilus influenzae type B
Meninge ACYW sanofi pasteur meningococcal infections Phase II
(second-generation Swiftwater, PA (800) 822-2463
meningococcal conjugate infant
vaccine)
meningococcal vaccine group B Novartis Vaccines Diagnostics meningococcal group B infections Phase II
quadrivalent recombinant Cambridge, MA (617) 871-7000
vaccine (4CMenB)
Menveo® Infants Novartis Vaccines Diagnostics prevention of meningococcal A, C, Y application submitted
meningococcal vaccine groups Cambridge, MA and W-135 infections (infants) (617) 871-7000
ACYW-135 conjugate vaccine
MMR vaccine GlaxoSmithKline prevention of measles, mumps and Phase II
(live attenuated trivalent Rsch. Triangle Park, NC rubella (888) 825-5249
vaccine)
Mosquirix™ GlaxoSmithKline malaria Phase III
malaria recombinant vaccine Rsch. Triangle Park, NC (888) 825-5249
MVA-BN® HIV BN ImmunoTherapeutics prevention and treatment of HIV-1 Phase I/II completed
HIV multiantigen vaccine (Bavarian Nordic) infection (650) 681-4660
Mountain View, CA
MVA-BN® Polytope BN ImmunoTherapeutics prevention of HIV infection Phase I
HIV vaccine (Bavarin Nordic) (650) 681-4660
Mountain View, CA
NB-1008 NanoBio prevention of influenza virus Phase I
(intranasal vaccine) Ann Arbor, MI infections (734) 302-4000
Medicines in Development Vaccines 2012 19
20. Medicines in Development for Vaccines
Infectious Diseases
Product Name Sponsor Indication Development Status
NDV-3 NovaDigm Therapeutics prevention of candidiasis, prevention Phase I
(recombinant protein vaccine) Grand Forks, ND of staphylococcal (MRSA) infections (701) 757-5161
Nimenrix™ GlaxoSmithKline prevention of meningococcal groups Phase III
MenACWY-TT conjugated Rsch. Triangle Park, NC A, C, Y and W-135 infections (888) 825-5249
vaccine (children)
-------------------------------------------------- -------------------------------------------
prevention of meningococcal groups Phase II
A, C, Y and W-135 infections (888) 825-5249
(adults, adolescents, infants)
NmVac JN-International Medical prevention of meningococcal groups Phase I
(meningococcal vaccine groups Omaha, NE A, C, Y, and W-135 infections (402) 884-3477
ACWY conjugate vaccine)
norovirus bivalent vaccine LigoCyte Pharmaceuticals norovirus infections Phase I
Bozeman, MT (406) 585-2733
norovirus monovalent vaccine LigoCyte Pharmaceuticals norovirus infections Phase I/II
Bozeman, MT (406) 585-2733
Optaflu® Novartis Vaccines Diagnostics prevention of influenza virus application submitted
influenza virus vaccine Cambridge, MA infections (617) 871-7000
PanBlok™ Protein Sciences prevention of influenza A virus H5N1 Phase I/II
influenza A virus H5N1 vaccine Meriden, CT subtype (pandemic) (800) 488-7099
parvovirus B19 vaccine Meridian Biosciences parvovirus infections Phase I/II
Cincinnati, OH (513) 271-3700
PENNVAX™-B Inovio Pharmaceuticals prevention and treatment of HIV Phase I
DNA vaccine (clade B) Blue Bell, PA infection (267) 440-4200
PENNVAX™-G Inovio Pharmaceuticals prevention of HIV infection Phase I
DNA vaccine (clade A, C, D) Blue Bell, PA (267) 440-4200
PER.C-flu vaccine Crucell prevention of influenza virus Phase II
Leiden, Netherlands infections www.crucell.com
PF-05212366 Pfizer adolescent meningitis Phase II
(MnB rLP2086) New York, NY (860) 732-5156
-------------------------------------------------- -------------------------------------------
infant meningitis Phase I
(860) 732-5156
PF-06290510 Pfizer staphylococcal infections Phase II
(4-antigen Staphylococcus New York, NY (860) 732-5156
aureus vaccine)
plague vaccine injectable DynPort Vaccine Yersinia infections Phase II
Frederick, MD (301) 607-5000
20 Medicines in Development Vaccines 2012
21. Medicines in Development for Vaccines
Infectious Diseases
Product Name Sponsor Indication Development Status
Preflucel™ Baxter Healthcare prevention of influenza virus Phase III
seasonal influenza virus vaccine Deerfield, IL infections (800) 422-9837
Pseudomonas aeruginosa sanofi pasteur prevention of ventilator-associated Phase I
antibody fragment product Swiftwater, PA pneumonia (800) 822-2463
PXVX-0103 PaxVax prevention of influenza A virus Phase I
(H5N1 influenza vaccine) Menlo Park, CA H5N1 infections www.paxvax.com
Q-LAIV Flu MedImmune seasonal influenza application submitted
(MEDI-3250 vaccine) Gaithersburg, MD (301) 398-0000
Quadracel® sanofi pasteur diphtheria, tetanus, pertussis and Phase III
diphtheria and tetanus toxoids Swiftwater, PA polio vaccine (in children 4-6 years (800) 822-2463
and acellular pertussis vaccine of age)
adsorbed combined with
inactivated poliomyelitis vaccine
rabies VRVg sanofi pasteur prevention of rabies infection Phase II
(purified vero rabies vaccine) Swiftwater, PA (800) 822-2463
respiratory syncytial virus VLP Novavax prevention of respiratory syncytial Phase I
vaccine Rockville, MD virus (RSV) infections (240) 268-2000
RiVax™ Soligenix prevention of ricin poisoning Phase I
ricin vaccine Princeton, NJ (609) 538-8200
(Orphan Drug)
rotavirus vaccine sanofi pasteur prevention of rotavirus infections Phase I
(live attenuated tetravalent oral Swiftwater, PA (800) 822-2463
vaccine)
rotavirus vaccine I321 Bharat Biotech prevention of rotavirus infections Phase I
Hyderabad, India www.bharatbiotech.com
rPA-102 Emergent BioSolutions anthrax Phase II
(recombinant protective antigen Rockville, MD (Fast Track) (301) 795-1800
anthrax vaccine)
Shigella vaccine Emergent BioSolutions Shigella infections Phase I
Rockville, MD (301) 795-1800
SparVax™ PharmAthene anthrax Phase II completed
recombinant protective antigen Annapolis, MD (pre- and post-exposure prevention) (410) 269-2600
(rPA) anthrax vaccine
Staphylococcus aureus vaccine Novartis Vaccines Diagnostics staphylococcal infections Phase I
Cambridge, MA (617) 871-7000
Medicines in Development Vaccines 2012 21
22. Medicines in Development for Vaccines
Infectious Diseases
Product Name Sponsor Indication Development Status
Staphylococcus aureus vaccine GlaxoSmithKline Gram-positive infections, Phase I/II
conjugate pentavalent Rsch. Triangle Park, NC staphylococcal infections (888) 825-5249
streptococcal B vaccine Emergent BioSolutions streptococcal infections Phase I
Rockville, MD (301) 795-1800
streptococcal B vaccine Novartis Vaccines Diagnostics prevention of streptococcal infections Phase II
conjugate Cambridge, MA (617) 871-7000
Streptococcus pneumoniae sanofi pasteur meningitis and penumonia Phase I
vaccine Swiftwater, PA (800) 822-2463
TCN-032 Theraclone Sciences influenza A virus infections Phase I
(mAb vaccine) Seattle, WA (206) 805-1600
TG-4040 Transgene hepatitis C Phase II
(vector-based therapeutic Rockville, MD (301) 816-5421
vaccine)
TransVax™ Astellas Pharma US prevention of cytomegalovirus Phase II
cytomegalovirus DNA vaccine Deerfield, IL infections (800) 695-4321
(Orphan Drug) Vical (858) 646-1100
San Diego, CA
tuberculosis recombinant sanofi pasteur prevention of tuberculosis Phase I
subunit vaccine Swiftwater, PA (800) 822-2463
tuberculosis vaccine Aerus Global TB Vaccine Foundation prevention of tuberculosis Phase I
Rockville, MD www.crucell.com
Crucell
Leiden, Netherlands
tularemia vaccine DynPort Vaccine prevention of tularemia Phase I
Frederick, MD (301) 607-5000
TUTI-16 Thymon HIV-1 infection Phase I/II
(synthetic lipopeptide vaccine) Short Hills, NJ (973) 467-9558
Typhella™ Emergent BioSolutions prevention of typhoid Phase II completed
typhoid vaccine oral Rockville, MD (301) 795-1800
typhoid vaccine Novartis Vaccines Institute for prevention of typhoid Phase II
Global Health (888) 669-6682
Siena, Italy
V114 Merck prevention of pneumococcal Phase II
(pneumococcal 15 valent Whitehouse Station, NJ infections (infants) (800) 672-6372
conjugate vaccine)
22 Medicines in Development Vaccines 2012